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2008). As the consequences of intrauterine oxygen restriction may 
extend into adulthood, adaptive mechanisms have evolved in the 
embryo to overcome the devastating effects of inadequate sup-
ply with oxygen. These include the synthesis of a fetal form of 
hemoglobin with improved oxygen binding affinity, a high cardiac 
output in relation to the effective oxygen needs, and a relatively low 
specific metabolic rate of most embryonic tissues (Martin, 2008; 
Thein et al., 2009).
Besides imposing the risk of hypoxia on the growing embryo 
tissue oxygenation may also serve as a physiological signal that 
directs the temporal and spatial gene expression during intrau-
terine  maturation.  The  importance  of  oxygen  as  a  signaling 
molecule in development becomes evident from the lethality of 
mouse embryos with targeted disruption of the genes encoding 
the hypoxia-inducible factors (HIFs). HIFs are heterodimeric basic 
helix–loop–helix transcription factors which bind to the RCGTG 
consensus sequence and function as master regulators of gene 
expression in hypoxia (Semenza et al., 1991; Webb et al., 2009). 
HIFs are composed of an oxygen-sensitive α-subunit and the con-
stitutive aryl hydrocarbon receptor nuclear translocator (Arnt, also 
called HIF-β). Three HIF-α genes exist in mammalian cells, which 
are expressed either ubiquitously (HIF-1α) or in a more restricted 
The feTus and hypoxia
During no other period of life our organism bears such a high risk 
of insufficient tissue oxygenation as it does prenatally. Fetal hypoxia 
in mammals can lead to intrauterine growth restriction and reduced 
birth weight, or may even impair normal organ formation (Webster 
and Abela, 2007; Hutter et al., 2010). Fetal programming refers to 
the situation that an early stimulus or insult operating at a sensi-
tive period of prenatal development results in long-term structural 
and functional changes of an individual (Barker, 2004). Placental 
pathologies that can lead to fetal programming are frequently asso-
ciated with hypoxia and oxidative stress. For example, placental 
villous explants from patients with preeclampsia, a severe form of 
pregnancy-induced arterial hypertension, secreted fourfold higher 
amounts of the soluble receptor-1 for vascular endothelial growth 
factor (VEGF) than tissue from healthy pregnant women (Ahmad 
and Ahmed, 2004). These findings suggested that villous explants 
in vitro retain a hypoxia memory, which may reflect long-term fetal 
programming (Ahmad and Ahmed, 2004). This and other inves-
tigations also provided evidence that elevated levels of the soluble 
VEGF receptor-1 can inhibit angiogenesis in preeclampsia thereby 
increasing the morbidity and mortality for mother and fetus due 
to endothelial dysfunction (reviewed in Mutter and Karumanchi, 
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doi: 10.3389/fnmol.2011.00004manner (HIF-2α, HIF-3α; Chen et al., 2009). The HIF-α subunits 
are highly unstable under normoxic conditions: hydroxylation of 
HIF-α at two conserved proline residues by the oxygen-dependent 
enzyme HIF prolyl-hydroxylase allows for the interaction of HIF 
with the von Hippel–Lindau E3 ubiquitin ligase complex and sub-
sequent proteasomal degradation (Jaakkola et al., 2001; reviewed in 
Semenza, 2004). Additionally, the factor inhibiting HIF-1 (FIH-1) 
hydroxylates an asparagine residue in the C-terminal transactiva-
tion domain (TAD) of HIF-α in normoxia thereby preventing its 
interaction with the transcriptional co-activator p300 (Koivunen 
et al., 2004). These molecular regulators of HIFs function as oxygen 
sensors in various tissues (Webb et al., 2009).
Strikingly, complete disruption of HIF-1α in mice resulted 
in a developmental arrest and embryonic lethality by E11 (Iyer 
et al., 1998; Ryan et al., 1998). Among other abnormalities Hif-
1α-deficient murine embryos (Hif-1α−/−) exhibited impaired vas-
cularization of various tissues in addition to neural tube defects 
and marked cell death within the cephalic mesenchyme (Iyer et al., 
1998; Ryan et al., 1998). Likewise, inactivation of the genes encod-
ing HIF-2α and HIF-1β caused embryonic lethality due to vascular 
defects, impaired hematopoiesis, and a failure of normal placental 
differentiation (Kozak et al., 1997; Peng et al., 2000; Scortegagna 
et al., 2003). The preterm death and the phenotypic abnormalities 
of murine embryos with targeted disruption of the genes encoding 
HIF-1α, HIF-2α, or HIF-1β indicate that oxygen sensing is indeed 
necessary for normal intrauterine development.
The Wilms’ Tumor gene, WT1
The Wilms’ tumor gene, WT1, is among the molecular downstream 
targets of HIF. Loss-of-function mutations in a childhood cancer 
of the kidney known as nephroblastoma or Wilms’ tumor testified 
WT1 as a tumor suppressor gene (Huff et al., 1991; Pelletier et al., 
1991a,b; Park et al., 1993). The disease affects approximately 1:10000 
children worldwide, usually around age five, but individuals with 
genetic predisposition can develop bilateral tumors even earlier in 
life. Since the WT1 gene is inactivated in only ∼15% of sporadic 
Wilms’ tumors, the genetic abnormalities underlying the major-
ity of nephroblastomas are currently unknown. Recent findings 
indicate that monoallelic mutations of the X-chromosome linked 
gene WTX (APC membrane recruitment 1 also called AMER1) 
may account for approximately one-third of Wilms’ tumors (Rivera 
et al., 2007).
The WT1 gene, which is in the focus of this article, spans more 
than 50 kb on the short arm of human chromosome 11 (11p13) and 
contains 10 exons (Gessler et al., 1992). It encodes a ∼55 kDa protein 
with four C-terminal Cys2-His2 zinc fingers allowing for sequence-
specific nucleic acid binding (Call et al., 1990; Gessler et al., 1990; 
reviewed in Scharnhorst et al., 2001). Other functional domains 
include a proline/glutamine-rich N-terminal sequence implicated 
in transcriptional activation, a self-association domain, and a puta-
tive RNA recognition motif (Kennedy et al., 1996). Overall, more 
than two dozens WT1 isoforms are generated by alternative mRNA 
splicing, translation initiation at variable start points, RNA edit-
ing, and post-translational modifications (reviewed in Scharnhorst 
et al., 2001). Of particular importance are two alternative splicing 
events that give rise to four different WT1 splice isoforms (Haber 
et al., 1991; Gessler et al., 1992). Alternative splicing of exon 5, which 
occurs only in mammals but in no other vertebrates analyzed so far 
(Kent et al., 1995), interposes 17 amino acids between the proline/
glutamine-rich N-terminus and the zinc finger domain of the WT1 
protein. Unexpectedly, selective ablation of the exon 5 containing 
Wt1 isoforms caused no obvious phenotype in mice suggesting 
functional redundancy among the different Wt1 molecules during 
embryonic development (Natoli et al., 2002). The usage of an alter-
native splice donor site at the end of exon 9 results in the insertion 
of three extra amino acids, lysine, threonine, serine (KTS), between 
the third and fourth zinc fingers (Haber et al., 1991). WT1 proteins 
with the KTS tripeptide have a reduced DNA binding affinity com-
pared to the −KTS forms (Laity et al., 2000). Evidence obtained from 
morphological and biochemical studies suggests that the prevalent 
WT1(+KTS) proteins are involved in post-transcriptional proc-
esses, whereas the WT1(−KTS) molecules act predominantly as 
transcription factors (Larsson et al., 1995; Caricasole et al., 1996; 
Davies et al., 1998; Niksic et al., 2004; Bor et al., 2006). Several 
dozens downstream candidate targets of WT1 have been identified 
including the genes for growth factors and their receptors, extracel-
lular matrix and cell adhesion molecules, transcription factors, and 
signal transducers (for review see Scharnhorst et al., 2001; Roberts, 
2005). However, the majority of these genes were assessed by co-
transfecting promoter–reporter constructs with WT1 expression 
plasmids, and only few candidates can be considered as bona fide 
targets that are regulated by WT1 in vivo.
Besides its function as a tumor suppressor WT1 is also required 
for normal embryogenesis. Mice with homozygous disruption of 
Wt1 (Wt1
−/−) are embryonic lethal and lack kidneys and gonads 
(Kreidberg et al., 1993). Other defects in Wt1 null mutant embryos 
pertain to the mesothelium, i.e., the epicardium and coelomic epi-
thelium (Moore et al., 1999), spleen (Herzer et al., 1999), adrenal 
glands (Moore et al., 1999), retina (Wagner et al., 2002b), and the 
olfactory epithelium (Wagner et al., 2005a). A frequent observation 
in Wt1 deficiency is an increased number of apoptotic cells in tissues 
that would normally express Wt1 in wild-type animals (Kreidberg 
et al., 1993; Wagner et al., 2002b, 2005b). It has therefore been 
proposed that WT1 proteins may rescue cells from apoptosis and 
permit other factors to promote cell differentiation. Hemizygosity 
for WT1 in humans is associated with genitourinary malforma-
tions suggesting that the WT1 gene dosage is relevant for normal 
development (Pelletier et al., 1991a).
Despite the importance of WT1 in embryogenesis and tumor 
formation little is known about the physiological mechanisms 
that control its expression. Several transcription factors have been 
reported to regulate the proximal WT1 promoter in transfection 
experiments including activation by Sp1 (Cohen et al., 1997) and 
Pax2 (Dehbi et al., 1996), and negative feedback inhibition by WT1 
itself (Malik et al., 1994; Rupprecht et al., 1994). Transgenic expres-
sion from a yeast artificial chromosome (YAC) carrying ∼280 kb of 
flanking sequence of the human WT1 gene was performed in an 
attempt to rescue the phenotype of Wt1-null embryos (Moore et al., 
1999). While this strategy proved successful in restoring the mor-
phology of the epicardium and diaphragm of Wt1-deficient mice, 
the kidney and gonad defects could not be rescued (Moore et al., 
1999). Consistently, in vitro studies confirmed that cis-  regulatory 
elements at far distance from the transcription start site are impor-
tant for normal WT1 levels (Scholz et al., 1997). Interestingly, recent 
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ventricular heart weights was found in several disease models of 
compensatory  cardiac  hypertrophy,  Wt1  was  significantly  up- 
regulated in heart tissue after myocardial infarction in rats (Wagner 
et al., 2002a). In contrast to the situation in sham-operated animals, 
which expressed Wt1 exclusively in the epicardium but in no other 
cell types in the heart, de novo expression of Wt1 was detected in 
myocardial blood vessels in the infarct border zone (Wagner et al., 
2002a). Further on, Wt1 in vascular cells was associated with a 
local increase of pro-angiogenic molecules, e.g., VEGF. Wt1 expres-
sion in the vasculature of the ischemic hearts could be mimicked 
by exposure of rats to either 8% ambient oxygen or 0.1% carbon 
monoxide (Wagner et al., 2002a). Although these and other results 
(Wagner et al., 2003) disclosed WT1 as an oxygen-regulated gene, 
at least in the heart, the functional importance of this regulatory 
mechanism remained elusive. A short recapitulation of the devel-
opmental events underlying formation of the epicardium and the 
presumed role of WT1 herein may bring some light into the dark.
WT1 in The developing epicardium
The epicardium originates from the proepicardial organ (PEO) 
which arises from the mesothelium of the septum transversum in 
mammalian embryos and the sinus venosus near the embryonic 
liver in birds (Männer et al., 2001; Ratajska et al., 2008). Expansion 
of the spreading epicardium on the outer heart surface occurs by 
cell proliferation. In the following stages a subset of epicardial cells 
loosen their contacts, detach from the basement membrane, and 
migrate in the space directly beneath the epicardium (reviewed 
in Männer et al., 2001; Gittenberger-de Groot et al., 2010). The 
delamination of epicardial cells is closely linked to a change in 
the differentiation state of these cells, which lose their apico-basal 
polarity and acquire a mesenchymal phenotype (Figure 1). This 
phenomenon, which has been referred to as epithelial-to-mesen-
chymal transition (EMT) is associated with a profound cytoskel-
etal remodeling that results in a spindle-shaped cell morphology 
and improved cell migration capacity (reviewed in Thiery and 
Sleeman, 2006; Guarino, 2007). Epicardium-derived mesenchy-
mal cells populate the myocardial tissue and differentiate there to 
interstitial fibroblasts and coronary vascular smooth muscle and 
endothelial cells (Mikawa and Gourdie, 1996; Dettman et al., 1998; 
Pérez-Pomares et al., 2002a; Wilting et al., 2007). Since epicardium-
derived mesenchymal cells can also differentiate to cardiac myocytes 
(Cai et al., 2008; Zhou et al., 2008) they have been considered as 
cardiovascular progenitor cells in the developing heart (Figure 1).
Where in this sequence of events does WT1 come into play 
and what is its function during epicardial development relating to 
the local oxygen concentration? WT1 is initially expressed in the 
proepicardium and the coelomic epithelium which gives rise to 
the parietal pericardium and the germinal epithelium (Carmona 
et al., 2001; Pérez-Pomares et al., 2002b). Alpha4integrin, whose 
product associates with β1- and β7-integrin subunits to form het-
erodimeric cell adhesion molecules (reviewed in Liu et al., 2000), 
was identified as a first candidate target gene of WT1 in (pro)epicar-
dial cells (Kirschner et al., 2006). Remarkably, embryos which lack 
α4integrin have similar epicardial defects as Wt1−/− mice suggesting 
that impaired α4integrin expression accounts at least in part for 
the abnormalities in Wt1-deficient hearts (Sengbusch et al., 2002). 
findings indicate that WT1 expression is regulated in vitro and in 
vivo by the local oxygen tension. This notion is based on the obser-
vation that exposure of adult rats at low ambient oxygen (8% O2) 
significantly increased Wt1 mRNA and protein levels in kidneys 
and hearts (Wagner et al., 2002a). Furthermore, HIF-1 protein in 
nuclear extracts from hypoxic cells bound to a hypoxia respon-
sive cis-element in the proximal WT1 promoter (Wagner et al., 
2003). Mutation of the HIF-1 binding site abrogated stimulation 
of the WT1 promoter by hypoxia in transient reporter gene assays 
(Wagner et al., 2003). While these findings identified tissue hypoxia 
as a stimulatory signal for WT1, the functional significance of an 
oxygen-dependent control of WT1 expression is just beginning to 
emerge. The following paragraphs highlight possible implications 
of this regulatory switch in embryonic development and tumor 
formation.
oxygen-dependenT WT1 expression in The hearT
The epicardium constitutes an epithelial sheath that is spread on 
the outer surface of the heart. It belongs to the few tissues which 
express WT1 continuously from early embryogenesis on through-
out adulthood. Remarkably, the hearts of Wt1-null mutant mouse 
embryos (Wt1−/−) exhibit severe muscular wall thinning with fre-
quent bleeding into the pericardial cavity (Kreidberg et al., 1993; 
Moore et al., 1999). Myocardial hypoplasia as in Wt1−/− embryos was 
also observed upon targeted disruption of other epicardial genes 
including those for vascular cell adhesion molecule-1 (VCAM-1; 
Kwee et al., 1995), α4integrin (Yang et al., 1995; Sengbusch et al., 
2002), RARα (Kastner et al., 1997), RXRα (Sucov et al., 1994), and 
FOG2 (Tevosian et al., 2000). Thus, normal myocardial growth dur-
ing embryogenesis appears to depend on mitogenic signals emanat-
ing from the WT1 expressing epicardium (Figure 1). This raises the 
interesting question of whether compensatory heart growth in the 
adult, e.g., in response to arterial hypertension, is related to changes 
in WT1 expression. A study addressing this issue yielded   intriguing 
FIgure 1 | Proposed role of hypoxia and WT1 in the developing heart. A 
major function of WT1 is the control of epithelial-to-mesenchymal transition 
(EMT) of epicardial cells. Epicardium-derived mesenchymal cells give rise to 
vascular endothelial and smooth muscle cells as well as interstitial fibroblasts 
and cardiomyocytes in the heart. RA, retinoic acid.
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thelial transition, in the developing kidney (Davies et al., 2004; 
Hohenstein and Hastie, 2006). Induction of the permanent kidney 
occurs through reciprocal interactions between the metanephric 
mesenchyme and the invading mesonephric (Wolffian) duct, which 
gives rise to the ureter (Quaggin and Kreidberg, 2008; Constantini 
and Kopan, 2010). Another important event during nephron for-
mation is the condensation and subsequent epithelialization of 
the metanephric mesenchyme around the branching ureteric bud 
tips (Quaggin and Kreidberg, 2008; Constantini and Kopan, 2010). 
Epithelial differentiation is disrupted in WT1-deficient embryonic 
kidneys, which fail to mature beyond the early inductive stages 
(Kreidberg et al., 1993). The highest levels of WT1 are usually found 
in podocytes of the kidneys, Sertoli cells of the testis, and mesothe-
lial cells (reviewed in Scharnhorst et al., 2001). These cell types 
share the capability of switching between an epithelial and mes-
enchymal phenotype, a process which is likely controlled by WT1. 
Interestingly, proteomic analysis of renal podocytes from a Denys–
Drash syndrome patient with a WT1 gene mutation revealed that 
of the 75 misexpressed proteins 43% were related to cytoskeletal 
components (Viney et al., 2007). This finding supports the notion 
that WT1 directs the expression of components of the cytoskeleton 
and regulators of its assembly during reciprocal transition between 
a mesenchymal and epithelial differentiation state.
Evidence has been provided that EMT is associated with a low 
oxygen microenvironment. For example, exposure of breast cancer 
cells to 1% O2 induced changes, e.g., down-regulation of epithelial 
marker proteins, enhanced vimentin expression, and cell migra-
tion, that are consistent with EMT (Lester et al., 2007). Hypoxia 
and HIFs can modulate EMT-triggering pathways through several 
mechanisms (Figure 2). These include direct regulation of EMT 
inducers and their receptors, changes in the expression of signaling 
molecules acting on EMT, and enhancement of functional inter-
action with EMT-associated nuclear factors (reviewed in Haase, 
2009). EMT inducers belong to the TGF-β growth factor family 
(Zavadil et al., 2004) and the Notch and Wnt/β-catenin signaling 
pathways (Gustafsson et al., 2005; Neth et al., 2007; Sahlgren et al., 
2008). Upon binding to its cognate receptors TGF-β stimulates 
EMT via SMAD-dependent expression of genes involved in cell 
proliferation, differentiation, and migration (reviewed in Zavadil 
and Bottinger, 2005). Non-SMAD-dependent pathways of TGF-β in 
EMT act along the MAPK-signaling cascade, which controls small 
Rho family GTPases thereby influencing cell motility (reviewed in 
Zavadil and Bottinger, 2005). Activation of Notch promotes EMT 
through induction of Snai1 and Snai2 (Timmerman et al., 2004), 
and through interfering with TGF-β/SMAD-mediated EMT via 
the hairy/enhancer-of-split-related transcriptional repressor Hey1 
(Zavadil et al., 2004). The role of the Wnt/β-catenin signaling path-
way as an inducer of EMT in development and cancer is also well 
established (Huber et al., 2005; Wu and Zhou, 2008).
Remarkably, the molecular signaling pathways of hypoxia and 
WT1, whose expression is increased at low oxygen tension via HIF-1 
activation (Wagner et al., 2003), converge on the level of EMT 
regulatory molecules (Figure 2). Thus, β-catenin enhances HIF-1 
target gene transcription, whereas physical interaction with HIF 
inhibits the transcriptional activity of β-catenin (Kaidi et al., 2007). 
Wnt/β-catenin downstream signaling is also negatively regulated by 
Thus, a physiological function of WT1 during early heart devel-
opment may consist in facilitating the attachment of epicardial 
progenitor cells to the outer surface of the heart through enhanced 
expression of cell adhesion molecules (Figure 1).
The developing epicardium is highly susceptible to hypoxia, 
and epicardial detachment was the first sign of hypoxic damage in 
mouse fetuses with reduced tissue oxygenation (Ream et al., 2008). 
Further on lowering the inspiratory oxygen concentration of preg-
nant mice from 21 to 8% O2 caused intrauterine growth restriction 
and severe myocardial thinning by E12.5 (Ream et al., 2008). These 
phenotypic abnormalities of hypoxic fetal hearts are reminiscent 
of the myocardial hypoplasia in Wt1-deficient murine embryos 
(Kreidberg et al., 1993; Moore et al., 1999). It is thus likely that 
myocardial growth promoting signals are generated in the devel-
oping epicardium, which requires a balanced oxygen environment 
and intact WT1 expression. Accordingly, mechanical removal of the 
epicardium from explants of chicken embryonic hearts caused a 
proliferation arrest of cardiac myocytes (Stuckmann et al., 2003). 
Likewise, blockade of retinoic acid or erythropoietin (Epo) signal-
ing from the epicardium inhibited cardiac myocyte proliferation 
and survival, and this effect could be reversed by administration 
of either exogenous Epo or retinoic acid, respectively (Stuckmann 
et al., 2003). Consistently, murine embryos which lack the genes 
encoding Epo and its receptor (Epo-R) exhibit thin walled ventri-
cles, partial detachment of the epicardium, and abnormal coronary 
vascular plexus (Wu et al., 1999). In wild-type murine embryos 
Epo-R is expressed in the epicardium and the endocardium of the 
heart but not in cardiomyocytes (Wu et al., 1999). These combined 
findings suggest that cardiac myocyte proliferation is stimulated 
by epicardium-derived mitogens which are under the reciprocal 
control of Epo and retinoic acid (Figure 1). Interestingly, transcrip-
tion of the genes encoding Epo, which is also oxygen-regulated, 
and its cognate receptor is activated by WT1 (Dame et al., 2006; 
Kirschner et al., 2008). Moreover, WT1 has been reported to repress 
the human but not the murine RARα1 promoter through bind-
ing to a GC-rich consensus motif (Goodyer et al., 1995). A highly 
conserved retinoic acid binding element was recently discovered 
in the wt1a gene from zebrafish (Bollig et al., 2009). This retinoic 
acid sensitive element is located in an enhancer region which directs 
promoter gene expression to the intermediate mesoderm (Bollig 
et al., 2009). Thus, oxygen-regulated WT1 may function as a major 
component within the complex network of molecules that control 
the signal transfer between epicardial cells and cardiomyocytes in 
the developing heart.
WT1 and epiThelial-To-mesenchymal TransiTion
Epithelial-to-mesenchymal transition of epicardial cells is crucial 
for the generation of cardiovascular progenitor cells in the heart 
(Wessels and Perez-Pomares, 2004). In an elegant study it was 
shown recently that WT1 is necessary for repression of the epithelial 
phenotype in epicardial cells and during embryonic stem cell differ-
entiation. Transcriptional activation by WT1 of the genes encoding 
Snail (Snai1) and E-cadherin (Cdh1) was proven as a critical step 
during EMT (Martinez-Estrada et al., 2010). Lack of EMT in Wt1−/− 
mutant embryonic stem cells caused a failure in the differentiation 
of some mesothelial lineages, which could be rescued by forced 
expression of Snail (Martinez-Estrada et al., 2010). Notably, Wt1 is 
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WID), which interacts with the immediate downstream effector of 
the frizzled receptor, Disheveled (Kim et al., 2010). The local oxygen 
environment controls the Notch pathway and the expression of 
TGF-β (Scheid et al., 2002; Schäffer et al., 2003; Chen et al., 2007; 
Sahlgren et al., 2008; Zheng et al., 2008), which is also regulated by 
WT1 (Dey et al., 1994; Jin et al., 1999). TGF-β has been reported 
to stimulate EMT in proepicardial tissue explants (Olivey et al., 
2006), and mice with targeted inactivation either of the TGF-β type 
III receptor (Compton et al., 2007) or the TGF-β type I receptor 
(Alk5; (Sridurongrit et al., 2008) exhibit cardiac defects resembling 
those in Wt1 deficiency (Moore et al., 1999; Wagner et al., 2005b). 
Thus, TGF-β signaling is a possible pathway along which WT1 
may regulate EMT in epicardial cells in relation to the local oxygen 
concentration.
WT1 and coronary blood vessel developmenT
As outlined above, cells destined to assemble the myocardial vas-
culature originate from the proepicardium. The epicardium and 
the subepicardial mesenchyme constitute a source for various cell 
lineages in the embryonic heart including coronary endothelial and 
smooth muscle cells, cardiac fibroblasts, and also cardiomyocytes 
(Mikawa and Gourdie, 1996; Dettman et al., 1998; Pérez-Pomares 
et al., 2002a; Wilting et al., 2007; Cai et al., 2008; Zhou et al., 2008). 
Considering the crucial role of WT1 in the formation of the epi-
cardium (Kreidberg et al., 1993; Moore et al., 1999) it is no longer 
surprising that normal vascularization of the heart is impaired in 
the absence of WT1. Indeed, blood vessel density was significantly 
reduced in the hearts of Wt1-null murine embryos at 15.5 d.p.c. 
compared to their wild-type littermates (Wagner et al., 2005b). 
Apoptosis of a significant number of cells in the Wt1-deficient epi-
cardium and subepicardial tissue suggests that Wt1 acts as a survival 
factor for mesenchymal cells in the heart (Wagner et al., 2005b). 
Detection of Wt1 protein in the vessel walls of wild-type embryonic 
hearts indicates that Wt1 may also fulfill a role in stabilizing the 
newly formed coronary vasculature (Wagner et al., 2005b). A likely 
downstream target of Wt1 in this function is the Ntrk2 gene, which 
encodes the high affinity neurotrophin receptor, TrkB (Klein et al., 
1992; Wagner et al., 2005b). The promoter of the Ntrk2 gene was 
trans-activated by Wt1 in vitro and in the embryonic epicardium 
in vivo (Wagner et al., 2005b). Inactivation of the genes encod-
ing either TrkB or its ligand, brain-derived neurotrophic factor 
(BDNF), caused myocardial vessel destabilization, and subsequent 
bleeding in the subepicardial mesenchyme (Donovan et al., 2000; 
Wagner et al., 2005b). BDNF–TrkB signaling is assumed to pro-
mote cell contact formation in the nascent vasculature through 
FIgure 2 | Molecular signaling pathways in epithelial-to-mesenchymal transition (eMT). For details see manuscript text.
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At these sites WT1 was frequently associated with proliferating 
cell nuclear antigen (PCNA), and WT1 silencing by RNAi signifi-
cantly lowered vascular endothelial cell proliferation and migration 
in vitro (Wagner et al., 2008). Vascular endothelial cells undergo 
profound structural and functional changes during branching ang-
iogenesis and it will be a challenging task to elucidate a possible 
role of WT1 in endothelial cell plasticity.
WT1 in Tumors
Wilms’ tumor gene has been proven to function as a suppressor of 
Wilms’ tumor growth by a multitude of genetic and experimental 
studies (reviewed in Scharnhorst et al., 2001; Rivera and Haber, 
2005). However, during the past few years it became increas-
ingly clear that WT1 is expressed at a rather high level in various 
malignancies including carcinomas of the lung (Oji et al., 2002), 
colon (Kösters et al., 2004), thyroid gland (Oji et al., 2003), breast 
(Loeb et al., 2001), pancreas (Oji et al., 2004a), brain (Oji et al., 
2004b), and the majority of Wilms’ tumors (Rivera and Haber, 
2005). The molecular mechanisms that account for the robust 
expression of WT1 in these diseases are not well understood. 
However, considering the low oxygen tensions in rapidly growing 
tumors (reviewed in Hockel and Vaupel, 2001), one can assume 
that local tissue hypoxia contributes to the increased WT1 levels 
in various carcinomas.
Most WT1 expressing tumors originate from tissues, which do 
normally not contain substantial amounts of WT1. The absence 
of WT1 gene mutations from these neoplasms has therefore been 
considered as circumstantial evidence for an oncogenic potential 
of WT1 (reviewed in Yang et al., 2007). Highly elevated WT1 
levels were also found in the bone marrow and peripheral blood 
of many leukemias compared to normal bone marrow and hemat-
opoietic progenitor cells (Miwa et al., 1992; Miyagi et al., 1993; 
Menssen et al., 1995). Increased WT1 expression correlated with 
a relatively low responsiveness to standard chemotherapy and 
a poor prognosis of most leukemias suggesting that wild-type 
WT1 contributes to the disease phenotype (Tamaki et al., 1999; 
Barragan et al., 2004; Chiusa et al., 2006). Consistently, in most 
but not all studies down-regulation of WT1 was associated with 
a reduced growth and rapid apoptosis of acute myeloic leukemia 
cells (Yamagami et al., 1996; Ito et al., 2006). The molecular sig-
naling pathways underlying the dual role (oncogene vs. tumor 
suppressor) of WT1 in tumor formation are not well understood 
but may involve variable target gene selection in different tis-
sues and/or changes in protein function due to physical inter-
action with partner molecules in a cell type-specific manner 
(Johnstone et al., 1996, reviewed in Roberts, 2006). For example, 
interaction with prostate apoptosis response-4 (par-4) through 
the zinc finger DNA binding domain shifted the effect of WT1 
from transcriptional activation to repression (Johnstone et al., 
1996). Co-transfection of wild-type par-4, but not of a mutant 
form defective of WT1 interaction, abrogated growth suppression 
caused by WT1 (Johnstone et al., 1996).
Interestingly, the mitochondrial serine protease HtrA2 was 
recently identified as a novel WT1 binding partner (Hartkamp 
et al., 2010). HtrA2 is thought to function as a tumor suppressor by 
limiting the activity of prosurvival oncogenes through proteolytic 
  maintaining  the  clustering  of  the  adherens  junction  molecule 
β-catenin (Dejana et al., 1999). It is noteworthy that TrkB expres-
sion, at least in neurons, is enhanced in hypoxia through activation 
by HIF-1 (Martens et al., 2007).
Remarkably, intravenous injection of the hypoxia marker EF5 
[2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) 
acetamide] revealed severely hypoxic tissue regions close to the ori-
gin of the major coronary arteries in avian embryos (Sugishita et al., 
2004; Wikenheiser et al., 2006). Incubation of chicken embryos 
at Hamburger and Hamilton (HH) stage 25 at low (15% O2) or 
high (40–75%) ambient oxygen caused malformations of coronary 
arteries at their proximal connections to the aorta (Wikenheiser 
et al., 2009). Local over-expression of HIF-1α increased the number 
of hemangioblasts and blood vessels at the base of the outflow tract 
(Wikenheiser et al., 2009). The vascular abnormalities in oxygen-
depleted chicken embryos are presumably due to the recruitment 
of epicardium-derived vascular progenitor cells to ectopic sites in 
the developing heart. Thus, a picture emerges according to which 
the formation of the coronary vascular system involves differential 
oxygen levels within the developing heart leading to regional acti-
vation of oxygen-dependent transcription factors such as HIF-1, 
WT1, and others. In the absence of a normal coronary vessel system 
myocardial growth restriction may occur when the diffusion capac-
ity for oxygen and nutrients from the ventricular blood is exceeded 
by the actual needs of the embryonic heart. Hence, disturbed myo-
cardial vascularization likely contributes to the ventricular wall 
thinning in Wt1-deficient murine embryos (Kreidberg et al., 1993; 
Moore et al., 1999).
WT1 and vascularizaTion of non-cardiac Tissues
It is still unclear whether the pro-vasculogenic role of WT1 is 
confined to the heart, or whether WT1 plays a role in blood ves-
sel formation in other tissues as well. Remarkable structural and 
functional analogies exist in the development of the heart and the 
gut. Similar to the heart, the gut is covered by a mesothelial enve-
lope which is thought to provide the source of vasculogenic cells 
(reviewed in Ratajska et al., 2008; Olivey and Svensson, 2010). By 
the combinatorial use of molecular biology techniques and vital cell 
fate tracing it has been demonstrated that Wt1 expressing serosal 
mesothelial cells are spread on the outer surface of the developing 
mouse gut, which is initially devoid of blood vessels (Wilm et al., 
2005). Subsequently, a subpopulation of cells undergoes EMT, 
migrates throughout the gut, and differentiates to smooth muscle 
cells of all major blood vessels in the intestine (Wilm et al., 2005). 
Considering these similarities of developmental events and the pre-
sumed role of hypoxia in EMT (Lester et al., 2007) it is tempting 
to speculate whether Wt1 fulfills related functions during blood 
vessel formation in the embryonic gut and heart. However, definite 
proof for a critical role of WT1 in vasculogenesis of the intestine 
still needs to be provided. In this regard, transgenic animal models 
which enable a developmental stage and tissue-specific inactivation 
of Wt1 will provide a major technical advancement.
     Wilms’ tumor gene protein was recently also detected in 
the vasculature of diverse tumors arising in the skin (Timár et al., 
2005), breast, endometrium, lung, and other organs (Wagner et al., 
2008; Dohi et al., 2010). In most cases, WT1 was not detected in 
blood vessels of adjacent normal tissue samples, but was restricted 
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of oncogenic KRAS (Vicent et al., 2010; Figure 4). Moreover, 
decreased WT1 target gene expression correlated with improved 
prognosis only in lung cancer patients whose genetic signature was 
indicative of oncogenic KRAS activation (Vicent et al., 2010). In 
another study, deletion of HIF-2α, but not of HIF-1α, was found 
to promote tumor formation in human KRAS-driven lung cancer 
cells (Mazumdar et al., 2010). This effect was attributed, at least in 
part, to a reduced expression of the candidate tumor suppressor 
gene Scgb3a1 in the absence of HIF-2α (Mazumdar et al., 2010; 
Figure 4). Enhanced levels of the activated, GTP-bound K-ras 
proto-oncogene in response to hypoxia were found in colon cancer 
cells with a wild-type KRAS gene (Zeng et al., 2010). These com-
bined findings testify that the oncogenic properties of WT1 are 
closely related to the KRAS signaling pathway which is also under 
control of the local oxygen environment. Hence, WT1 and hypoxia 
may functionally synergize on the level of KRAS-dependent cell 
cycle control.
concluding remarks
The product of the Wilms’ tumor gene, WT1, acts as a critical gate-
keeper at the crossroad of normal development and cancer. The 
back and forth transition between a mesenchymal and epithelial 
cellular state appears to be a major target event for WT1 action. 
To gain a complete picture of the multiple functions of WT1, it is 
mandatory to identify bona fide downstream effectors of the vari-
ous protein isoforms in conjunction with their interacting partner 
molecules.
Moreover, it will necessary to decipher the physiological mecha-
nisms that regulate WT1 in normal and tumor cells. Previous find-
ings indicated that tissue oxygenation determines WT1 expression, 
and that HIFs can stimulate transcription of the WT1 gene at low 
ambient oxygen. Future studies will need to address the question of 
whether oxygen-dependent regulation of WT1 also pertains to the 
degradation. All four major WT1 protein isoforms were cleaved by 
HtrA2 at multiple sites in response to cytotoxic stress, and block-
ade of HtrA2 activity prevented the proteolysis of WT1 under 
proapoptotic conditions (Hartkamp et al., 2010). The latter obser-
vations are remarkable as a recent proteome-wide screen of more 
than 1000 proteins detected only 15 substrates of HtrA2 (Vande 
Walle et al., 2007), with very few apoptosis-related mitochondrial 
proteins among those (Johnson and Kaplitt, 2009). The release of 
HtrA2 from mitochondria and subsequent induction of apoptosis 
was stimulated by reactive oxygen species in vascular endothe-
lial cells (Liu et al., 2010). Moreover, oxidative stress resulting 
from tissue reperfusion after ischemic injury activated the HtrA2 
pathway in the brain (Saito et al., 2004). It is thus conceivable 
that tissue oxygenation does not only regulate the expression of 
WT1, but may also modulate its function through interfering 
with HtrA2 signaling (Figure 3). A potential downstream mecha-
nism of WT1 in drug-induced cell death involves the proapoptotic 
genes c-Myc and JunB, which are normally suppressed by WT1 
(Hartkamp et al., 2010). Proteolytic cleavage of WT1 by HtrA2 in 
response to cytotoxic stress resulted in high levels of c-Myc and 
JunB and subsequent apoptosis of cancer cells (Hartkamp et al., 
2010). Accordingly, HtrA2-mediated cleavage may represent a 
critical switch that alleviates the oncogenic potential of WT1 in 
the presence of cytotoxic stress (Figure 3). It will be a thrilling task 
for future studies to determine whether   cleavage-resistant WT1 
variants exist, and to explore their   potential   functions in normal 
development and cancer. Further on, the effect of other sorts of 
cellular stress on WT1-HtrA2 interaction needs to be investigated.
     WT1 has recently been reported to act downstream of the 
KRAS oncogene in the control of cell proliferation and senes-
cence (Vicent et al., 2010). The KRAS gene, which belongs to the 
RAS gene family, encodes a membrane-bound 21 kDa guanosine 
triphosphate (GTP)-binding protein. Inactivation of Wt1 caused 
senescence of KRAS expressing mouse embryonic fibroblasts and 
inhibited tumor progression in an animal model of KRAS-driven 
lung cancer (Vicent et al., 2010; Figure 4). In contrast, deletion or 
FIgure 4 | Proposed roles of WT1 and hypoxia-inducible factor HIF-2α in 
KRAS-driven tumor formation. The prooncogenic effects of WT1 are closely 
linked to KRAS signaling, and inactivation of WT1 inhibits KRAS-dependent 
tumor formation. Deletion of HIF-2α promotes KRAS-driven tumorigenesis 
through down-regulation of the tumor suppressor Scgba1.
FIgure 3 | role of the mitochondrial serine protease HtrA2 in the 
regulation of WT1 function. Activation of HtrA2 by cytotoxic stress causes 
degradation of WT1 protein, thereby increasing the proapoptotic transcription 
factors c-Myc and JunB.
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Scholz and Kirschner  Hypoxia and the Wilms’ tumor genealternatively spliced. Hypoxia can regulate alternative mRNA splic-
ing in several ways which include changes in splicing factor levels 
as well as activities (Webby et al., 2009). It is therefore tempting to 
speculate whether oxygen-dependent regulation of alternative WT1 
mRNA splicing contributes to the functional complexity of WT1 
proteins. A thorough investigation of these issues may provide novel 
insights into important regulatory mechanisms during embryonic 
development and tissue repair, and may eventually pave the way 
for innovative therapeutic strategies in a broad range of diseases.
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